



P&T Committee Review Meeting Minutes

Subject:	Louisiana Department of Health Medicaid Pharmaceutical and Therapeutic Committee Review
Location:	Zoom Conference: https://magellanhealth.zoom.us/webinar/register/WN_ulhYwfRwQYCIUYHNE45QOg
Date:	May 5, 2023
Members Present:	▪ Ben Orlando, RPh ▪ Dr. Charles C. Coleman ▪ Dr. Jill Comeau ▪ Tammy D. Hart ▪ J. Scott Black
LDH Staff Present:	▪ Germaine Becks-Moody, PhD, BHSF ▪ Sue Fontenot, RPh ▪ Melwyn Wendt, PharmD
Contractors Present:	▪ Hind Douiki, PharmD, Magellan Medicaid Administration ▪ Kara Delaney, PharmD, Magellan Medicaid Administration
Others Present:	Presenters are listed in the minutes and sign in sheets and others in attendance from LDH, Bureau of Health Services Financing, Pharmacy Benefits Section upon request.

Call to Order

Mr. Ben Orlando, Chairman, called the meeting to order at or around 9:00 a.m.

Parliamentary Business

- A. **Introduction of Members/Roll Call.** Ms. Becks-Moody called the roll of the P&T Committee members.
- B. **Approval of November 4, 2022 Meeting Minutes.** Mr. Orlando indicated the members cannot vote on approval of the Minutes due to the meeting not being held in-person.

P & T Committee Review Virtual Process

Ms. Wendt indicated this meeting will be held virtually due to lack of quorum and, as such, there will be no voting or making motions; only discussions will be made, which the Secretary will take into consideration in order to make final decisions that will be implemented on 7/1/2023.

Ms. Douiki also provided an overview of the virtual P&T committee meeting process. She indicated the format will be similar to a live meeting, except there will be no voting. She added that the virtual meeting is technologically set up so that only panelists (P&T committee members, LDH staff, and Magellan staff) will be able to speak. Members of the public will be able to listen and only speak when allowed by the Chair and when it is their turn to provide public testimony.

Reports

Ms. Wendt informed the P&T Committee members that there are currently 6 MCOs in LA Medicaid, in addition to FFS. She indicated the overall PDL Compliance rate is high and LDH is now working towards a single pharmacy benefits manager, which they are planning to implement in October of 2023 in order to simplify processes and procedures for providers and recipients.

New Business

A. Explanation of TOP\$, Monographs and Cost Sheets

Ms. Douiki provided an overview of the TOP\$ supplemental rebate pool that Louisiana Medicaid participates in. She presented information about clinical and financial components of the recommendation process. She also summarized the supplemental rebate process. She indicated to the members that they should have received clinical documents, in the form of Therapeutic Class Reviews or New Drug Updates...etc. The committee members should also have cost sheets which include relative values, rather than actual numbers, in order to comply with the privacy laws regarding rebates.

B. Therapeutic Class Reviews of Spring Drug Classes/Drug Manufacturer Testimony

In accordance with state law and the P&T Committee's bylaws, the following provided public testimony or answered questions raised by the Committee during the Committee's review.

Presenter	Representing	Drug/Issue
Arlene Mejia	Pierre Fabre	Hemangeol
Katie Queen	Children's Hospital Baton Rouge	GLP-1 agonists
Alexandra Wallem	Eli Lilly	Mounjaro
Michael Cook	UMC New Orleans	GLP-1 agonists
Kathy Kiammona	Novo Nordisk	Rybelsus
Catherine Hudson	New Orleans University Medical Center Hospital	GLP-1 agonists

Bryan Wilson	Genentech	Ocrevus
Patrick Reed	United Therapeutics	Tyvaso and Tyvaso DPI
**NOTE: Names of speakers who were present and yielded their time back were not captured.		

Acne Agents, Topical

Recommendations for the PDL are:

- CLINDAMYCIN / BENZOYL PEROXIDE (BENZAclin) (TOPICAL)
- CLINDAMYCIN / BENZOYL PEROXIDE (DUAC) (TOPICAL)
- CLINDAMYCIN PHOSPHATE GEL (TOPICAL)
- CLINDAMYCIN PHOSPHATE LOTION (TOPICAL)
- CLINDAMYCIN PHOSPHATE MED. SWAB (TOPICAL)
- CLINDAMYCIN PHOSPHATE SOLUTION (TOPICAL)
- ERYTHROMYCIN GEL (TOPICAL)
- ERYTHROMYCIN SOLUTION (TOPICAL)
- RETIN-A CREAM (TOPICAL)

There were no further discussions made by the committee about this class.

Analgesics Narcotics, Long

Recommendations for the PDL are:

- BUPRENORPHINE (AG) (TRANSDERM)
- BUPRENORPHINE (TRANSDERM)
- BUTRANS (TRANSDERM)
- FENTANYL (TRANSDERM)
- MORPHINE ER TABLET (ORAL)
- XTAMPZA ER (ORAL)

There were no further discussions made by the committee about this class.

Analgesics Narcotics, Short

Recommendations for the PDL are:

- APAP / CODEINE ELIXIR (ORAL)
- APAP / CODEINE TABLET (ORAL)
- HYDROCODONE / APAP SOLUTION (ORAL)
- HYDROCODONE / APAP TABLET (ORAL)
- HYDROMORPHONE TABLET (ORAL)
- MORPHINE DISP SYRIN (ORAL)
- MORPHINE IR TABLET (ORAL)
- OXYCODONE / APAP TABLET (ORAL)
- OXYCODONE TABLET (ORAL)

- TRAMADOL (ORAL)
- TRAMADOL / APAP (ORAL)

There were no further discussions made by the committee about this class.

Androgenic Agents

Recommendations for the PDL are:

- ANDRODERM (TRANSDERM)
- TESTOSTERONE GEL (VOGELXO) (TRANSDERM)
- TESTOSTERONE GEL (AG) (VOGELXO) (TRANSDERM)
- TESTOSTERONE GEL PACKET (AG) (VOGELXO) (TRANSDERM)
- TESTOSTERONE GEL PUMP (ANDROGEL) (TRANSDERM)
- TESTOSTERONE GEL PUMP (AG) (VOGELXO) (TRANSDERM)

There were no further discussions made by the committee about this class.

Angiotensin Modulator Combinations

Recommendations for the PDL are:

- AMLODIPINE / BENAZEPRIL (ORAL)
- AMLODIPINE / OLMESARTAN (AG) (ORAL)
- AMLODIPINE / OLMESARTAN (ORAL)
- AMLODIPINE / VALSARTAN (ORAL)

There were no further discussions made by the committee about this class.

Angiotensin Modulators

Recommendations for the PDL are:

- BENAZEPRIL (ORAL)
- BENAZEPRIL HCTZ (ORAL)
- ENALAPRIL (ORAL)
- ENALAPRIL HCTZ (ORAL)
- ENALAPRIL SOLUTION (AG) (ORAL)
- ENALAPRIL SOLUTION (ORAL)
- ENTRESTO (ORAL)
- FOSINOPRIL (ORAL)
- FOSINOPRIL HCTZ (ORAL)
- IRBESARTAN (ORAL)
- IRBESARTAN HCTZ (ORAL)
- LISINOPRIL (ORAL)
- LISINOPRIL HCTZ (ORAL)
- LOSARTAN (ORAL)
- LOSARTAN HCTZ (ORAL)

- OLMESARTAN (AG) (ORAL)
- OLMESARTAN (ORAL)
- OLMESARTAN HCTZ (AG) (ORAL)
- OLMESARTAN HCTZ (ORAL)
- QUINAPRIL (ORAL)
- QUINAPRIL HCTZ (ORAL)
- RAMIPRIL (ORAL)
- VALSARTAN (ORAL)
- VALSARTAN HCTZ (ORAL)

There were no further discussions made by the committee about this class.

Antibiotics, GI

Recommendations for the PDL are:

- METRONIDAZOLE TABLET (ORAL)
- NEOMYCIN (ORAL)
- TINIDAZOLE (ORAL)
- VANCOMYCIN CAPSULE (AG) (ORAL)
- VANCOMYCIN CAPSULE (ORAL)

There were no further discussions made by the committee about this class.

Antibiotics, Inhaled

Recommendations for the PDL are:

- BETHKIS (INHALATION)
- TOBRAMYCIN (TOBI) (INHALATION)

There were no further discussions made by the committee about this class.

Antibiotics, Topical

Recommendations for the PDL are:

- MUPIROCIN OINTMENT (TOPICAL)

There were no further discussions made by the committee about this class.

Antibiotics, Vaginal

Recommendations for the PDL are:

- CLINDESSE (VAGINAL)
- METRONIDAZOLE (VAGINAL)
- NUVESSA (VAGINAL)

There were no further discussions made by the committee about this class.

Anticoagulants

Recommendations for the PDL are:

- ELIQUIS (ORAL)
- ELIQUIS DOSE PACK (ORAL)
- ENOXAPARIN SODIUM VIAL (AG) (SUBCUTANEOUS)
- ENOXAPARIN SODIUM VIAL (SUBCUTANEOUS)
- ENOXAPARIN SYRINGE (AG) (SUBCUTANE.)
- ENOXAPARIN SYRINGE (SUBCUTANE.)
- PRADAXA (ORAL)
- WARFARIN (ORAL)
- XARELTO (ORAL)
- XARELTO DOSE PACK (ORAL)

There were no further discussions made by the committee about this class.

Antivertigo/Antiemetic Agents

Recommendations for the PDL are:

- MECLIZINE (AG) (ORAL)
- MECLIZINE (ORAL)
- METOCLOPRAMIDE SOLUTION (ORAL)
- METOCLOPRAMIDE TABLET (ORAL)
- METOCLOPRAMIDE VIAL (INJECTION)
- ONDANSETRON ODT (ORAL)
- ONDANSETRON SOLUTION (ORAL)
- ONDANSETRON TABLETS (ORAL)
- ONDANSETRON VIAL (INTRAVEN)
- PROCHLORPERAZINE (ORAL)
- PROMETHAZINE (RECTAL)
- PROMETHAZINE AMPUL (INJECTION)
- PROMETHAZINE SYRUP (ORAL)
- PROMETHAZINE TABLET (ORAL)
- PROMETHAZINE VIAL (INJECTION)
- SCOPOLAMINE (TRANSDERM)

There were no further discussions made by the committee about this class.

Antifungals, Oral

Recommendations for the PDL are:

- CLOTRIMAZOLE (MUCOUS MEM)
- FLUCONAZOLE SUSPENSION (ORAL)
- FLUCONAZOLE TABLET (ORAL)

- GRISEOFULVIN SUSPENSION (ORAL)
- NYSTATIN SUSPENSION (ORAL)
- NYSTATIN TABLET (ORAL)
- TERBINAFINE (ORAL)

There were no further discussions made by the committee about this class.

Antifungals, Topical

Recommendations for the PDL are:

- CLOTRIMAZOLE CREAM RX (TOPICAL)
- CLOTRIMAZOLE SOLUTION RX (TOPICAL)
- CLOTRIMAZOLE-BETAMETHASONE CREAM (TOPICAL)
- KETOCONAZOLE CREAM (TOPICAL)
- KETOCONAZOLE SHAMPOO (TOPICAL)
- NYSTATIN CREAM (TOPICAL)
- NYSTATIN OINT (TOPICAL)
- NYSTATIN POWDER (TOPICAL)
- NYSTATIN-TRIAMCINOLONE CREAM (TOPICAL)
- NYSTATIN-TRIAMCINOLONE OINT (TOPICAL)

There were no further discussions made by the committee about this class.

Antimigraine Agents, Other

Recommendations for the PDL are:

- AJOVY AUTOINJECTOR (SUBCUTANEOUS)
- AJOVY AUTOINJECTOR 3-PK (SUBCUTANEOUS)
- AJOVY (SUBCUTANEOUS)
- EMGALITY PEN (SUBCUTANEOUS)
- EMGALITY SYRINGE 120 MG (SUBCUTANEOUS)
- NURTEC ODT (ORAL)
- UBRELVY (ORAL)

There were no further discussions made by the committee about this class.

Antimigraine Agents, Triptans

Recommendations for the PDL are:

- IMITREX (NASAL)
- RIZATRIPTAN ODT (ORAL)
- RIZATRIPTAN TABLET (ORAL)
- SUMATRIPTAN (AG) (NASAL)
- SUMATRIPTAN (NASAL)
- SUMATRIPTAN (ORAL)

- SUMATRIPTAN VIAL (SUBCUTANE.)

There were no further discussions made by the committee about this class.

Antiparasitics, Topical

Recommendations for the PDL are:

- NATROBA (TOPICAL)
- PERMETHRIN CREAM (TOPICAL)

There were no further discussions made by the committee about this class.

Antivirals, Oral

Recommendations for the PDL are:

- ACYCLOVIR CAPSULE (ORAL)
- ACYCLOVIR SUSPENSION (ORAL)
- ACYCLOVIR TABLET (ORAL)
- FAMCICLOVIR (ORAL)
- OSELTAMIVIR CAPSULE (ORAL)
- OSELTAMIVIR SUSPENSION (ORAL)
- VALACYCLOVIR (ORAL)

There were no further discussions made by the committee about this class.

Antivirals, Topical

Recommendations for the PDL are:

- ACYCLOVIR OINTMENT (TOPICAL)

There were no further discussions made by the committee about this class.

Beta Blockers

Recommendations for the PDL are:

- ACEBUTOLOL (ORAL)
- ATENOLOL (ORAL)
- ATENOLOL / CHLORTHALIDONE (ORAL)
- BISOPROLOL (ORAL)
- BISOPROLOL HCTZ (ORAL)
- BYSTOLIC (ORAL)
- CARVEDILOL (ORAL)
- LABETALOL (ORAL)
- METOPROLOL (ORAL)
- METOPROLOL XL (AG) (ORAL)

- METOPROLOL XL (ORAL)
- NADOLOL (ORAL)
- NEBIVOLOL (ORAL)
- PROPRANOLOL ER (AG) (ORAL)
- PROPRANOLOL ER (ORAL)
- PROPRANOLOL SOLUTION (ORAL)
- PROPRANOLOL TABLET (ORAL)
- SOTALOL (ORAL)

There were no further discussions made by the committee about this class.

Bladder Relaxant Preparations

Recommendations for the PDL are:

- FESOTERODINE ER (ORAL)
- MYRBETRIQ (ORAL)
- OXYBUTYNIN ER (ORAL)
- OXYBUTYNIN SYRUP (ORAL)
- OXYBUTYNIN TABLET (ORAL)
- SOLIFENACIN (ORAL)
- TOVIAZ (ORAL)

There were no further discussions made by the committee about this class.

Bone Resorption Suppression and Related Agents

Recommendations for the PDL are:

- ALENDRONATE TABLETS (ORAL)
- CALCITONIN SALMON (NASAL)
- IBANDRONATE TABLETS (ORAL)
- RALOXIFENE (ORAL)

There were no further discussions made by the committee about this class.

BPH Treatments

Recommendations for the PDL are:

- ALFUZOSIN (ORAL)
- DOXAZOSIN (AG) (ORAL)
- DOXAZOSIN (ORAL)
- DUTASTERIDE (ORAL)
- FINASTERIDE (ORAL)
- TAMSULOSIN (ORAL)
- TERAZOSIN (ORAL)

There were no further discussions made by the committee about this class.

Calcium Channel Blockers

Recommendations for the PDL are:

- AMLODIPINE (ORAL)
- DILTIAZEM CAPSULE ER (ORAL)
- DILTIAZEM TABLET (ORAL)
- FELODIPINE ER (ORAL)
- NIFEDIPINE ER (ORAL)
- NIFEDIPINE IR (ORAL)
- VERAPAMIL TABLET (ORAL)
- VERAPAMIL TABLET ER (ORAL)

There were no further discussions made by the committee about this class.

Cephalosporins and Related Antibiotics

Recommendations for the PDL are:

- AMOXICILLIN/CLAV SUSPENSION (ORAL)
- AMOXICILLIN/CLAV SUSPENSION (AG) (ORAL)
- AMOXICILLIN/CLAV TABLET (ORAL)
- AMOXICILLIN/CLAV TABLET (AG) (ORAL)
- CEFADROXIL CAPSULE (ORAL)
- CEFDINIR CAPSULE (ORAL)
- CEFDINIR SUSPENSION (ORAL)
- CEFPROZIL SUSPENSION (ORAL)
- CEFPROZIL TABLET (ORAL)
- CEFUROXIME TABLET (ORAL)
- CEPHALEXIN CAPSULE (ORAL)
- CEPHALEXIN SUSPENSION (ORAL)

There were no further discussions made by the committee about this class.

Cystic Fibrosis

Recommendations for the PDL are:

- All of the drugs in this class are recommended nonpreferred

There were no further discussions made by the committee about this class.

Fluoroquinolones, Oral

Recommendations for the PDL are:

- CIPROFLOXACIN TABLET (ORAL)
- LEVOFLOXACIN TABLET (ORAL)

There were no further discussions made by the committee about this class.

GI Motility, Chronic

Recommendations for the PDL are:

- AMITIZA (ORAL)
- LINZESS (ORAL)
- MOVANTIK (ORAL)
- RELISTOR SYRINGE (SUBCUTANE.)
- RELISTOR VIAL (SUBCUTANE.)

There were no further discussions made by the committee about this class.

Glucagon Agents

Recommendations for the PDL are:

- BAQSIMI (NASAL)
- GLUCAGON (INJECTION)
- GLUCAGON EMERGENCY KIT (LILLY) (INJECTION)
- ZEGALOGUE AUTOINJECTOR (SUBCUTANEOUS)

There were no further discussions made by the committee about this class.

Growth Factors

Recommendations for the PDL are:

- All of the drugs in this class are recommended nonpreferred

There were no further discussions made by the committee about this class.

Growth Hormone

Recommendations for the PDL are:

- GENOTROPIN CARTRIDGE (INJECTION)
- GENOTROPIN DISP SYRIN (INJECTION)
- NORDITROPIN PEN (INJECTION)

There were no further discussions made by the committee about this class.

H. Pylori Treatment

Recommendations for the PDL are:

- PYLERA (ORAL)

There were no further discussions made by the committee about this class.

HAE Treatments

Recommendations for the PDL are:

- HAEGARDA (SUB-Q)
- ICATIBANT (SUBCUT)

There were no further discussions made by the committee about this class.

HIV/AIDS

Recommendations for the PDL are:

- All of the drugs in this class are recommended preferred

There were no further discussions made by the committee about this class.

Hypoglycemics, Alpha-Glucosidase Inhibitors

Recommendations for the PDL are:

- ACARBOSE (ORAL)

There were no further discussions made by the committee about this class.

Hypoglycemics, Incretin Mimetics/Enhancers

Recommendations for the PDL are:

- BYETTA PENS (SUBCUTANE.)
- JANUMET (ORAL)
- JANUMET XR (ORAL)
- JANUVIA (ORAL)
- JENTADUETO (ORAL)
- OZEMPIC (SUBCUTANE.)
- TRADJENTA (ORAL)
- TRULICITY (SUBCUTANE.)
- VICTOZA (SUBCUTANE.)

After a few physicians spoke and asked for GLP1-Receptor Agonists to be used for obesity too, Ms. Wendt indicated that currently, the state plan in general does not pay for drugs to treat obesity. She indicated they have had some discussions with their medical directors and they are trying to move forward with coverage. However, this will require a state plan amendment. Ms. Fontenot provided her email address and Mel's email address to the physicians for special cases to be considered and discussed with LA Medicaid's Medical Director.

Hypoglycemics, Insulin and Related Agents

Recommendations for the PDL are:

- APIDRA SOLOSTAR PEN (SUBCUTANE.)
- APIDRA VIAL (SUBCUTANE.)
- HUMALOG CARTRIDGE (SUBCUTANE.)
- HUMALOG JUNIOR KWIKPEN (SUBCUTANE.)

- HUMALOG MIX PEN (SUBCUTANE.)
- HUMALOG MIX VIAL (SUBCUTANE.)
- HUMALOG PEN (SUBCUTANE.)
- HUMALOG VIAL (SUBCUTANE.)
- HUMULIN 500 U/M PEN (SUBCUTANE.)
- HUMULIN 500 U/M VIAL (SUBCUTANE.)
- HUMULIN 70/30 PEN OTC (SUBCUTANE.)
- HUMULIN 70/30 VIAL OTC (SUBCUTANE.)
- HUMULIN VIAL OTC (SUBCUTANE.)
- INSULIN ASPART CARTRIDGE (AG)
- INSULIN ASPART PEN (AG) (SUBCUTANEOUS)
- INSULIN ASPART VIAL (AG) (SUBCUTANEOUS)
- INSULIN ASPART/INSULIN ASPART PROTAMINE INSULIN PEN (AG) (SUBCUTANEOUS)
- INSULIN ASPART/INSULIN ASPART PROTAMINE VIAL (AG) (SUBCUTANEOUS)
- INSULIN GLARGINE PEN (SUBCUTANE.)
- INSULIN GLARGINE VIAL (SUBCUTANE.)
- INSULIN LISPRO JUNIOR KWIKPEN (AG) (SUBCUTANEOUS)
- INSULIN LISPRO PEN (AG) (SUBCUTANEOUS)
- INSULIN LISPRO PROTAMINE MIX KWIKPEN (AG) (SUBCUTANEOUS)
- INSULIN LISPRO VIAL (AG) (SUBCUTANEOUS)
- LANTUS SOLOSTAR PEN (SUBCUTANE.)
- LANTUS VIAL (SUBCUTANE.)
- LEVEMIR PENS (SUBCUTANE.)
- LEVEMIR VIAL (SUBCUTANE.)
- NOVOLOG CARTRIDGE (SUBCUTANE.)
- NOVOLOG MIX PEN (SUBCUTANE.)
- NOVOLOG MIX VIAL (SUBCUTANE.)
- NOVOLOG PEN (SUBCUTANE.)
- NOVOLOG VIAL (SUBCUTANE.)

There were no further discussions made by the committee about this class.

Hypoglycemics, Meglitinides

Recommendations for the PDL are:

- NATEGLINIDE (ORAL)
- REPAGLINIDE (ORAL)

There were no further discussions made by the committee about this class.

Hypoglycemics, Metformins

Recommendations for the PDL are:

- GLIPIZIDE-METFORMIN (ORAL)
- GLYBURIDE-METFORMIN (ORAL)

- METFORMIN (ORAL)
- METFORMIN ER (GLUCOPHAGE XR) (ORAL)

There were no further discussions made by the committee about this class.

Hypoglycemics, SGLT2

Recommendations for the PDL are:

- FARXIGA (ORAL)
- INVOKAMET (ORA
- INVOKANA (ORAL)
- JARDIANCE (ORAL)
- SYNJARDY (ORAL)
- XIGDUO XR (ORAL)

There were no further discussions made by the committee about this class.

Hypoglycemics, Sulfonylureas

Recommendations for the PDL are:

- GLIMEPIRIDE (ORAL)
- GLIPIZIDE (ORAL)
- GLIPIZIDE ER (ORAL)
- GLYBURIDE (ORAL)
- GLYBURIDE MICRONIZED (ORAL)

There were no further discussions made by the committee about this class.

Hypoglycemics, TZD

Recommendations for the PDL are:

- PIOGLITAZONE (ORAL)

There were no further discussions made by the committee about this class.

Immunosuppressives, Oral

Recommendations for the PDL are:

- AZATHIOPRINE (ORAL)
- CYCLOSPORINE, MODIFIED CAPSULE (ORAL)
- CYCLOSPORINE SOFTGEL (ORAL)
- MYCOPHENOLATE MOFETIL CAPSULE (ORAL)
- MYCOPHENOLATE MOFETIL TABLET (ORAL)
- MYCOPHENOLIC ACID (ORAL)
- RAPAMUNE SOLUTION (ORAL)

- RAPAMUNE TABLET (ORAL)
- TACROLIMUS (ORAL)

There were no further discussions made by the committee about this class.

Lincosamides/Oxazolidinones/Streptogramins

Recommendations for the PDL are:

- CLINDAMYCIN CAPSULES (ORAL)
- CLINDAMYCIN PALMITATE SOLUTION (ORAL)
- LINEZOLID TABLET (AG) (ORAL)
- LINEZOLID TABLET (ORAL)

There were no further discussions made by the committee about this class.

Lipotropics, Other

Recommendations for the PDL are:

- CHOLESTYRAMINE/SUCROSE (ORAL)
- COLESTIPOL GRANULES (ORAL)
- COLESTIPOL TABLET (ORAL)
- EZETIMIBE (ORAL)
- FENOFIBRATE CAPSULE (LOFIBRA) (ORAL)
- FENOFIBRATE TABLET (LOFIBRA) (ORAL)
- FENOFIBRATE TABLET (TRICOR) (ORAL)
- GEMFIBROZIL (ORAL)
- NIACIN ER (ORAL)
- PRALUENT PEN (SUBCUTANEOUS)

There were no further discussions made by the committee about this class.

Lipotropics, Statins

Recommendations for the PDL are:

- ATORVASTATIN (ORAL)
- LOVASTATIN (ORAL)
- PRAVASTATIN (ORAL)
- ROSUVASTATIN (ORAL)
- SIMVASTATIN TABLET (ORAL)

There were no further discussions made by the committee about this class.

Macrolides/Ketolides

Recommendations for the PDL are:

- AZITHROMYCIN PACKET (AG) (ORAL)

- AZITHROMYCIN SUSPENSION (ORAL)
- AZITHROMYCIN TABLET (ORAL)
- CLARITHROMYCIN TABLET (ORAL)
- ERYTHROMYCIN BASE TABLET DR (ORAL)

There were no further discussions made by the committee about this class.

Multiple Sclerosis Agents

Recommendations for the PDL are:

- AVONEX (INTRAMUSC.)
- AVONEX PEN (INTRAMUSC.)
- BETASERON KIT (SUBCUTANE.)
- COPAXONE 20 MG/ML (SUBCUTANE.)
- COPAXONE 40 MG/ML (SUBCUTANE.)
- DALFAMPRIDINE ER (AG) (ORAL)
- DALFAMPRIDINE ER (ORAL)
- DIMETHYL FUMARATE DR (AG) (ORAL)
- DIMETHYL FUMARATE DR (ORAL)
- DIMETHYL FUMARATE DR STARTER PACK (ORAL)
- FINGOLIMOD (ORAL)
- KESIMPTA (SUBCUTANE.)

There were no further discussions made by the committee about this class.

Nitrofurantoin Derivatives

Recommendations for the PDL are:

- NITROFURANTOIN MACROCRYSTALS CAPSULES (AG) (ORAL)
- NITROFURANTOIN MACROCRYSTALS CAPSULES (ORAL)
- NITROFURANTOIN MONO-MACRO CAPSULES (ORAL)

There were no further discussions made by the committee about this class.

Opiate Dependence Treatments

Recommendations for the PDL are:

- BUPRENORPHINE HCL (SUBLINGUAL)
- BUPRENORPHINE/NALOXONE TAB (SUBLINGUAL)
- NALOXONE SPRAY (AG) (NASAL)
- NALOXONE SPRAY (NASAL)
- NALOXONE SYRINGE (INJECTION)
- NALOXONE VIAL (INJECTION)
- NALTREXONE (ORAL)
- NARCAN SPRAY (NASAL)

- SUBLOCADE (SUBCUTANEOUS)
- SUBOXONE FILM (SUBLINGUAL)
- VIVITROL (INTRAMUSC)
- ZUBSOLV (SUBLINGUAL)

Mr. Ben Orlando asked Ms. Wendt about how the OTC version of Naltrexone will be covered. She responded that the plan only covers limited OTC medications, but changes may have to be made. Ms. Fontenot added that a state amendment would have to be made in order to cover more OTCs, a process that takes about 6 months to complete.

PAH Agents, Oral and Inhaled

Recommendations for the PDL are:

- AMBRISENTAN (ORAL)
- BOSENTAN TABLET (AG) (ORAL)
- BOSENTAN TABLET (ORAL)
- REVATIO SUSPENSION (ORAL)
- SILDENAFIL TABLET (ORAL)
- TADALAFIL (ADCIRCA) (ORAL)
- TRACLEER TABLET (ORAL)

There were no further discussions made by the committee about this class.

Pancreatic Enzymes

Recommendations for the PDL are:

- CREON (ORAL)
- ZENPEP (ORAL)

There were no further discussions made by the committee about this class.

Pediatric Vitamin Preparations

Recommendations for the PDL are:

- FLUORIDE/VITAMINS A,C,AND D DROPS (ORAL)
- MULTIVITAMINS WITH FLUORIDE DROPS (ORAL)
- MULTIVITS WITH IRON & FLUORIDE DROPS (ORAL)
- PEDI MVI NO.16 WITH FLUORIDE TAB CHEW (ORAL)
- PEDI MVI NO.17 WITH FLUORIDE CHEW (ORAL)

There were no further discussions made by the committee about this class.

Phosphate Binders

Recommendations for the PDL are:

- CALCIUM ACETATE CAPSULE (ORAL)
- RENVELA TABLET (ORAL)

There were no further discussions made by the committee about this class.

Pituitary Suppressive Agents, LHRH

Recommendations for the PDL are:

- FENSOLVI (SUBCUTANEOUS)
- LEUPROLIDE ACETATE (SUB-Q)
- LUPRON DEPOT (INTRAMUSC)
- LUPRON DEPOT KIT (INJECTION)
- LUPRON DEPOT-PED (INJECTION)
- LUPRON DEPOT-PED KIT (INJECTION)
- SYNAREL (NASAL)

There were no further discussions made by the committee about this class.

Platelet Aggregation Inhibitors

Recommendations for the PDL are:

- ASPIRIN/DIPYRIDAMOLE (ORAL)
- BRILINTA (ORAL)
- CLOPIDOGREL (ORAL)
- DIPYRIDAMOLE (ORAL)
- PRASUGREL (ORAL)

There were no further discussions made by the committee about this class.

Pleuromutilins

Recommendations for the PDL are:

- All of the drugs in this class are recommended nonpreferred

There were no further discussions made by the committee about this class.

Potassium Binders

Recommendations for the PDL are:

- LOKELMA (ORAL)
- SODIUM POLYSTYRENE SULFONATE (ORAL)

There were no further discussions made by the committee about this class.

Proton Pump Inhibitors

Recommendations for the PDL are:

- LANSOPRAZOLE CAPSULES (ORAL)
- NEXIUM SUSPENSION (ORAL)
- OMEPRAZOLE (ORAL)

- PANTOPRAZOLE (ORAL)
- PROTONIX SUSPENSION (ORAL)

There were no further discussions made by the committee about this class.

Sinus Node Inhibitors

Recommendations for the PDL are:

- Corlanor is currently the only agent in this class; it was recommended nonpreferred

There were no further discussions made by the committee about this class.

Skeletal Muscle Relaxants

Recommendations for the PDL are:

- BACLOFEN (ORAL)
- CYCLOBENZAPRINE (ORAL)
- METHOCARBAMOL (ORAL)
- TIZANIDINE TABLETS (ORAL)

There were no further discussions made by the committee about this class.

Tetracyclines

Recommendations for the PDL are:

- DOXYCYCLINE HYCLATE CAPSULE (ORAL)
- DOXYCYCLINE HYCLATE TABLET (ORAL)
- DOXYCYCLINE MONOHYDRATE 100 MG CAPSULE (AG) (ORAL)
- DOXYCYCLINE MONOHYDRATE 100 MG CAPSULE (ORAL)
- DOXYCYCLINE MONOHYDRATE 50 MG CAPSULE (AG) (ORAL)
- DOXYCYCLINE MONOHYDRATE 50 MG CAPSULE (ORAL)
- DOXYCYCLINE MONOHYDRATE TABLET (ORAL)
- MINOCYCLINE CAPSULES (ORAL)

There were no further discussions made by the committee about this class.

Ulcerative Colitis Agents

Recommendations for the PDL are:

- APRISO (ORAL)
- BALSALAZIDE (ORAL)
- MESALAMINE (CANASA) (AG) (RECTAL)
- MESALAMINE (CANASA) (RECTAL)
- SULFASALAZINE (AG) (ORAL)

- SULFASALAZINE (ORAL)
- SULFASALAZINE DR (AG) (ORAL)

There were no further discussions made by the committee about this class.

Uterine Disorder Treatments

Recommendations for the PDL are:

- MYFEMBREE (ORAL)
- ORIAHNN (ORAL)
- ORILISSA (ORAL)

There were no further discussions made by the committee about this class.

Vasodilators, Coronary

Recommendations for the PDL are:

- BIDIL (ORAL)
- ISOSORBIDE DINITRATE (ORAL)
- ISOSORBIDE DINIT/HYDRALAZINE TABLET (AG) (ORAL)
- ISOSORBIDE DINTRATE/HYDRALAZINE (ORAL)
- ISOSORBIDE MONONITRATE (ORAL)
- ISOSORBIDE MONONITRATE SR (ORAL)
- NITRO-BID OINT. (TRANSDERM)
- NITROGLYCERIN (AG) (SUBLINGUAL)
- NITROGLYCERIN (SUBLINGUAL)
- NITROGLYCERIN (AG) (TRANSDERM)
- NITROGLYCERIN (TRANSDERM)

There were no further discussions made by the committee about this class.

Hepatitis C Agents

Recommendations for the PDL are:

- PEGASYS SYRINGE (SUB-Q)
- PEGASYS VIAL (SUBCUTANE.)
- RIBAVIRIN TABLET (ORAL)
- SOFOSBUVIR/VELPATASVIR (AG) (ORAL)

There were no further discussions made by the committee about this class.

Single Drug Reviews

In accordance with state law and the P&T Committee's bylaws, the following provided public testimony or answered questions raised by the Committee during the Committee's review.

Presenter	Representing	Drug/Issue
Sean Hammond	Axsome	Auvelity
**NOTE: Names of speakers who were present and yielded their time back were not captured.		

The single drugs were reviewed, and their recommendations are:

Antidepressants, SSRIs

Recommendations for the PDL are:

- AUVELITY (ORAL) - recommended NPD

Colony Stimulating Factors

Recommendations for the PDL are:

- FYLNETRA (SUBCUTANEOUS) – recommended Preferred
- STIMUFEND SYRINGE (SUBCUTANEOUS) – recommended NPD
- ROLVEDON SYRINGE (SUBCUTANEOUS) – recommended NPD

Cytokine and CAM Antagonists

Recommendations for the PDL are:

- AMJEVITA AUTOINJECTOR LC (SUBCUTANEOUS) - recommended NPD
- AMJEVITA SYRINGE (SUBCUTANEOUS) - recommended NPD
- AMJEVITA AUTOINJECTOR HC (SUBCUTANEOUS) - recommended NPD
- SOTYKTU (ORAL) - recommended NPD
- SPEVIGO (INTRAVEN.) - recommended NPD

Hemophilia Treatment

Recommendations for the PDL are:

- HEMGENIX (INTRAVEN)- recommended NPD

Oncology, Oral - Hematologic

Recommendations for the PDL are:

- REZLIDHIA (ORAL)- recommended NPD

Oncology, Oral – Other

Recommendations for the PDL are:

- LYTGobi (ORAL)– recommended NPD

Stimulants and Related Agents

Recommendations for the PDL are:

- XELSTRYM (TRANSDERMAL)– recommended NPD

Other Changes

Antipsychotics

Recommendations for the PDL are:

- LATUDA (ORAL)– recommended NPD
- LURASIDONE (ORAL)– recommended preferred

Proposed Therapeutic Classes to be Reviewed at Next Meeting

The committee members were shown the list of therapeutic classes that will be reviewed on the November 2023 meeting.

Next Meeting Date


The tentative date for the next P&T committee meeting is 10/25/2023.

Other Business

Ms. Wendt thanked all of the P&T committee members for attending. Mr. Orlando thanked LDH and Magellan for the work being put. DR. Coleman indicated he will not be available on 10/25/2023, and Mr. Orlando stated that date is subject to change.

Adjournment

The meeting adjourned at or about 10:58 am CT.

 10/20/24

Ben Orlando Date
Chairman P&T Committee